AU3625200A - Inhibition of pkc to treat permeability failure - Google Patents

Inhibition of pkc to treat permeability failure

Info

Publication number
AU3625200A
AU3625200A AU36252/00A AU3625200A AU3625200A AU 3625200 A AU3625200 A AU 3625200A AU 36252/00 A AU36252/00 A AU 36252/00A AU 3625200 A AU3625200 A AU 3625200A AU 3625200 A AU3625200 A AU 3625200A
Authority
AU
Australia
Prior art keywords
pkc
inhibition
treat
permeability
failure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU36252/00A
Inventor
George Liang King
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Joslin Diabetes Center Inc
Original Assignee
Joslin Diabetes Center Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Joslin Diabetes Center Inc filed Critical Joslin Diabetes Center Inc
Publication of AU3625200A publication Critical patent/AU3625200A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • External Artificial Organs (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU36252/00A 1999-03-12 2000-03-10 Inhibition of pkc to treat permeability failure Abandoned AU3625200A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12404399P 1999-03-12 1999-03-12
US60124043 1999-03-12
PCT/US2000/006405 WO2000053013A1 (en) 1999-03-12 2000-03-10 Inhibition of pkc to treat permeability failure

Publications (1)

Publication Number Publication Date
AU3625200A true AU3625200A (en) 2000-09-28

Family

ID=22412423

Family Applications (1)

Application Number Title Priority Date Filing Date
AU36252/00A Abandoned AU3625200A (en) 1999-03-12 2000-03-10 Inhibition of pkc to treat permeability failure

Country Status (2)

Country Link
AU (1) AU3625200A (en)
WO (1) WO2000053013A1 (en)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10501812A (en) * 1994-06-20 1998-02-17 スミスクライン・ビーチャム・コーポレイション Endothelin receptor antagonist
US5929106A (en) * 1997-10-27 1999-07-27 Smithkline Beecham Corporation Endothelin receptor antagonists

Also Published As

Publication number Publication date
WO2000053013A1 (en) 2000-09-14
WO2000053013A8 (en) 2001-04-05

Similar Documents

Publication Publication Date Title
AU3920900A (en) Compounds and methods to treat cardiac failure and other disorders
AU2001260400A1 (en) Use of hydrogenotrophic acetogenic strains for preventing or treating digestive disorders
AU2001266068A1 (en) Treatment of mineral substrates
AU6465400A (en) Inhibition of action potentials
AU3791601A (en) Treatment of coal
AU2520799A (en) Quantification by inhibition of amplification
AU3529399A (en) Well treatment for water restriction
AUPP303498A0 (en) Inhibition of gram positive bacteria
AU5531599A (en) Novel cdk inhibitors having flavone structure
AU6229699A (en) Beta-amyloid formation inhibitors
AU3566299A (en) Valve for drainage of left ventricle
IL135466A0 (en) Enzymatic modification of sterols
AU6274299A (en) Inhibition of pak activation of raf-1
IL140324A0 (en) Inhibition of transcription factor nf-kb
AU4369000A (en) Inhibition of complement action
AU2001245741A1 (en) Antisense inhibition of adam10 expression
AU5673099A (en) Inhibitors of amyloid formation
AU7104500A (en) Use of rafp to inhibit or prevent apoptosis
AU3625200A (en) Inhibition of pkc to treat permeability failure
AU2001293874A1 (en) System to prevent snoring
AUPP910699A0 (en) Inhibitor of lipoxygenase pathways
AU5969300A (en) Pressure treatment of cells
AU2001286052A1 (en) Improvements relating to water treatment
AU2017800A (en) Purification of water
AU2001256278A1 (en) Use of cse inhibitors for treating heart failure

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase